Glaukos (NYSE: GKOS) director Leana Wen awarded 2,987 stock options at $106.52

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Glaukos Corp director Leana Wen received a grant of stock options, and the amended Form 4 corrects their exercise price. On May 28, 2026 she was granted options for 2,987 shares of common stock at an exercise price of $106.52 per share, expiring on May 28, 2036. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the grant date. After this grant, she holds 2,987 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WEN LEANA

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,987	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 2,987 shares (Direct, null)

Footnotes (1)

This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.

Key Figures

Option grant size: 2,987 options Exercise price: $106.52 per share Prior incorrect price: $53.57 per share +3 more

6 metrics

Option grant size 2,987 options Stock Option (Right to Buy) granted May 28, 2026

Exercise price $106.52 per share Corrected exercise price for May 28, 2026 grant

Prior incorrect price $53.57 per share Incorrect exercise price reported in original Form 4

Underlying shares 2,987 shares Common stock underlying the option grant

Expiration date May 28, 2036 Option term end date for the grant

Post-grant derivative holdings 2,987 options Total options held following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, Director Compensation Policy, vests in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"incorrectly reported the exercise price of options granted"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Director Compensation Policy financial

"Granted pursuant to the Issuer's Director Compensation Policy."

vests in full financial

"Vests in full on the one-year anniversary of grant date."

Form 4A regulatory

"This Form 4A amends a Form 4 filed June 1, 2026"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/23/2026 - 07:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEN LEANA

(Last)

(First)

(Middle)

C/O GLAUKOS CORPORATION

ONE GLAUKOS WAY

(Street)

ALISO VIEJO

CALIFORNIA

92656

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/01/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$106.52⁽¹⁾	05/28/2026		A		2,987		05/28/2027⁽²⁾	05/28/2036	Common Stock	2,987	$0	2,987	D

Explanation of Responses:

1. This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.

2. Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.

	Diana Scherer, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did GLAUKOS Corp (GKOS) report for Leana Wen?

GLAUKOS Corp reported that director Leana Wen received a grant of 2,987 stock options on May 28, 2026. The options relate to common stock and were issued as part of the company’s Director Compensation Policy, reflecting routine equity-based compensation for board service.

What is the corrected exercise price of Leana Wen’s GLAUKOS (GKOS) stock options?

The amended filing corrects the exercise price of Leana Wen’s options to $106.52 per share. An earlier Form 4 had mistakenly reported the price as $53.57, and this Form 4/A clarifies the accurate exercise price for the May 28, 2026 option grant.

How many GLAUKOS (GKOS) shares are covered by Leana Wen’s stock option grant?

Leana Wen’s stock option grant covers 2,987 shares of GLAUKOS common stock. These options give her the right to buy that number of shares at a fixed exercise price of $106.52 per share, subject to vesting conditions and the stated expiration date.

When do Leana Wen’s GLAUKOS (GKOS) stock options vest and expire?

The options vest in full on the one-year anniversary of the May 28, 2026 grant date. They carry an expiration date of May 28, 2036, giving a ten-year term from grant during which vested options can potentially be exercised at the fixed strike price.

Why did GLAUKOS (GKOS) file an amended Form 4/A for Leana Wen?

The company filed an amended Form 4/A to correct the reported exercise price of options granted to Leana Wen. The original filing listed $53.57 per share, but the accurate exercise price is $106.52, and the amendment updates the disclosure to reflect this correct figure.

Is Leana Wen’s GLAUKOS (GKOS) option grant a direct holding?

Yes, the filing shows Leana Wen’s 2,987 stock options as a direct holding. After the grant, her total derivative holdings reported in this filing are 2,987 options, all held directly, with no indirect ownership entities disclosed for this specific transaction.